Cargando…

Determinants of Resistance to Checkpoint Inhibitors

The development of immune checkpoint inhibitors (ICIs) has drastically altered the landscape of cancer treatment. Since approval of the first ICI for the treatment of advanced melanoma in 2011, several therapeutic agents have been Food and Drug Administration (FDA)-approved for multiple cancers, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Linda, Theodorescu, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084564/ https://www.ncbi.nlm.nih.gov/pubmed/32111080 http://dx.doi.org/10.3390/ijms21051594

Ejemplares similares

Checkpoint Inhibitors and the Gut
por: Tran, Tuan, et al.
Publicado: (2022)

Mechanisms of resistance to immune checkpoint inhibitors
por: Jenkins, Russell W, et al.
Publicado: (2018)

Mechanism of resistance to immune checkpoint inhibitors
por: Pandey, Manu R., et al.
Publicado: (2019)

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Sharma, Revati, et al.
Publicado: (2021)

Mechanisms of resistance to immune checkpoint inhibitors
por: Nagasaki, Joji, et al.
Publicado: (2022)

Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
por: Perrier, Alexandre, et al.
Publicado: (2020)

The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
por: Koustas, Evangelos, et al.
Publicado: (2020)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
por: Fenton, Sarah E., et al.
Publicado: (2019)

Immune checkpoint inhibitor resistance in soft tissue sarcoma
por: Eulo, Vanessa, et al.
Publicado: (2022)

Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
por: Dosset, Magalie, et al.
Publicado: (2020)

Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
por: Seto, Tiffany, et al.
Publicado: (2019)

Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
por: Li, Yinuo, et al.
Publicado: (2023)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Checkpoint Inhibitors and Hepatotoxicity
por: Malnick, Stephen D. H., et al.
Publicado: (2021)

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
por: Karaki, Soumaya, et al.
Publicado: (2016)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
por: Gong, Jun, et al.
Publicado: (2018)

Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
por: Baxter, Mark A., et al.
Publicado: (2021)

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
por: Vukadin, Sonja, et al.
Publicado: (2021)

Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects
por: Chen, Xunrui, et al.
Publicado: (2022)

Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance
por: Weng, Chao-Yuan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
por: Lao, Yefang, et al.
Publicado: (2022)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023)

Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
por: To, Kenneth K. W., et al.
Publicado: (2023)

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
por: Pawłowska, Anna, et al.
Publicado: (2023)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2023)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)

Structure and Optimization of Checkpoint Inhibitors
por: Picardo, Sarah L., et al.
Publicado: (2019)

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
por: Fujiwara, Yu, et al.
Publicado: (2020)

Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
por: Rodriguez-Pascual, Jesus, et al.
Publicado: (2019)

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
por: De Lorenzo, Stefania, et al.
Publicado: (2022)

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Masson, Claire, et al.
Publicado: (2023)

Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer
por: Qian, Fang-Fei, et al.
Publicado: (2020)

The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook
por: Tran, Linh Chi, et al.
Publicado: (2023)

The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond
por: Gilon, Dan, et al.
Publicado: (2022)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e9gpg9hf0h737s63t4598daf2j